# ğŸ§¬ In vivo CAR-T æœ¬å‘¨æœ€æ–°æ–‡çŒ®å‘¨æŠ¥

> æ›´æ–°æ—¥æœŸ: 2026-01-10 | ç»Ÿè®¡èŒƒå›´: è¿‡å» 7 å¤© | å…³é”®è¯: In vivo CAR-T

## ğŸ“˜ æœ€æ–°ç»¼è¿° (Reviews)
---
### [Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.](https://pubmed.ncbi.nlm.nih.gov/41513408/)
- **æœŸåˆŠ**: *Journal for immunotherapy of cancer*
- **æ‘˜è¦**: Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has...

### [Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.](https://pubmed.ncbi.nlm.nih.gov/41490986/)
- **æœŸåˆŠ**: *Biomolecules & therapeutics*
- **æ‘˜è¦**: Cancer immunotherapy represents a paradigm-shifting achievement in oncology. Particularly, chimeric antigen receptor (CAR)-T cell therapy utilizing ge...

## ğŸ”¬ æœ€æ–°ç ”ç©¶è®ºæ–‡ (Articles)
---
### [Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.](https://pubmed.ncbi.nlm.nih.gov/41513407/)
- **æœŸåˆŠ**: *Journal for immunotherapy of cancer*
- **æ‘˜è¦**: Engineering chimeric antigen receptor (CAR) T cells with logic-gated synthetic Notch (synNotch) receptor circuits can enhance specificity and mitigate...

### [PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters.](https://pubmed.ncbi.nlm.nih.gov/41507351/)
- **æœŸåˆŠ**: *Communications biology*
- **æ‘˜è¦**: The combination of chimeric antigen receptor (CAR)-T cell therapy with immune checkpoint blockade (ICB) using anti-PD-1 has been demonstrated to enhan...

### [HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.](https://pubmed.ncbi.nlm.nih.gov/41501787/)
- **æœŸåˆŠ**: *Cell communication and signaling : CCS*
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T cell therapy has shown success in hematological malignancies, but its efficacy against solid tumors remains limited....

### [Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.](https://pubmed.ncbi.nlm.nih.gov/41501251/)
- **æœŸåˆŠ**: *Nature biomedical engineering*
- **æ‘˜è¦**: Major challenges facing chimeric antigen receptor (CAR)-T cell therapy for solid tumours include the immunosuppressive tumour microenvironment and the...

### [Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors.](https://pubmed.ncbi.nlm.nih.gov/41500474/)
- **æœŸåˆŠ**: *Biochemical pharmacology*
- **æ‘˜è¦**: In current clinical applications, there are challenges with using chimeric antigen receptor (CAR)-T cells to effectively treat solid tumors. These cha...

### [The LXRÎ²/NF-ÎºB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.](https://pubmed.ncbi.nlm.nih.gov/41496523/)
- **æœŸåˆŠ**: *Oncoimmunology*
- **æ‘˜è¦**: Liver X receptor Î² (LXRÎ²) is a key transcription factor involved in lipid metabolism and immune regulation, yet its functional role in tumor-infiltrat...

### [In Vivo Generation and Manipulation of CAR-T-mimicking Cells via Magnetic Bispecific Nano-antibody for Solid Tumor Therapy.](https://pubmed.ncbi.nlm.nih.gov/41495981/)
- **æœŸåˆŠ**: *Advanced materials (Deerfield Beach, Fla.)*
- **æ‘˜è¦**: The therapeutic efficacy of chimeric antigen receptor (CAR)-T cell therapy in combating solid tumors remains constrained, primarily due to inadequate ...

### [CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.](https://pubmed.ncbi.nlm.nih.gov/41495526/)
- **æœŸåˆŠ**: *Nature cancer*
- **æ‘˜è¦**: Insufficient functional T cell persistence impedes therapeutic success of chimeric antigen receptor (CAR) therapies. Here we performed a CAR-adapted b...

### [Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy.](https://pubmed.ncbi.nlm.nih.gov/41490421/)
- **æœŸåˆŠ**: *Cancer research*
- **æ‘˜è¦**: Chimeric antigen receptor (CAR)-T cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic ...

### [Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.](https://pubmed.ncbi.nlm.nih.gov/41490267/)
- **æœŸåˆŠ**: *Blood*
- **æ‘˜è¦**: Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the rela...

